Imperial College London
Portrait Picture

ProfessorPaulFarrell

Faculty of Medicine, Department of Infectious Disease

Professor of Tumour Virology
 
 
 
//

Contact

 

+44 (0)20 7594 2005p.farrell Website

 
 
//

Location

 

Section of VirologyNorfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Zha:2021:10.1002/advs.202002919,
author = {Zha, S and Chau, H-F and Chau, WY and Chan, LS and Lin, J and Lo, KW and Cho, WC-S and Yip, YL and Tsao, SW and Farrell, PJ and Feng, L and Di, JM and Law, G-L and Lung, HL and Wong, K-L},
doi = {10.1002/advs.202002919},
journal = {Advanced Science},
pages = {1--15},
title = {Dual-targeting peptide-guided approach for precision delivery and cancer monitoring by using a safe upconversion nanoplatform},
url = {http://dx.doi.org/10.1002/advs.202002919},
volume = {8},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Using EpsteinBarr virus (EBV)induced cancer cells and HeLa cells as a comparative study model, a novel and safe dualEBVoncoproteinstargeting pHresponsive peptide engineering, coating, and guiding approach to achieve precision targeting and treatment strategy against EBVassociated cancers is introduced. Individual functional peptide sequences that specifically bind to two overexpressed EBVspecific oncoproteins, EBNA1 (a latent cellular protein) and LMP1 (a transmembrane protein), are engineered in three different ways and incorporated with a pHsensitive tumor microenvironment (TME)cleavable linker onto the upconversion nanoparticles (UCNP) NaGdF4:Yb3+, Er3+@NaGdF4 (UCNPPn, n = 5, 6, and 7). A synergistic combination of the transmembrane LMP1 targeting ability and the pH responsiveness of UCNPPn is found to give specific cancer differentiation with higher cellular uptake and accumulation in EBVinfected cells, thus a lower dose is needed and the side effects and health risks from treatment would be greatly reduced. It also gives responsive UC signal enhancement upon targeted dualprotein binding and shows efficacious EBV cancer inhibition in vitro and in vivo. This is the first example of simultaneous imaging and inhibition of two EBV latent proteins, and serves as a blueprint for nextgeneration peptideguided precision delivery nanosystem for the safe monitoring and treatment against one specific cancer.
AU  - Zha,S
AU  - Chau,H-F
AU  - Chau,WY
AU  - Chan,LS
AU  - Lin,J
AU  - Lo,KW
AU  - Cho,WC-S
AU  - Yip,YL
AU  - Tsao,SW
AU  - Farrell,PJ
AU  - Feng,L
AU  - Di,JM
AU  - Law,G-L
AU  - Lung,HL
AU  - Wong,K-L
DO  - 10.1002/advs.202002919
EP  - 15
PY  - 2021///
SN  - 2198-3844
SP  - 1
TI  - Dual-targeting peptide-guided approach for precision delivery and cancer monitoring by using a safe upconversion nanoplatform
T2  - Advanced Science
UR  - http://dx.doi.org/10.1002/advs.202002919
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000605170500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://onlinelibrary.wiley.com/doi/10.1002/advs.202002919
UR  - http://hdl.handle.net/10044/1/86625
VL  - 8
ER  -
Download